Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pediatric RRMS trial of dimethyl fumarate versus peginterferon beta-1a versus placebo
MOH_2019-07-02_007245Phase 3Completed
- Sponsor
- Biogen
- Start
- Apr 2019
- Modality
- Small Molecules, Interferons → Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of dimethyl fumarate and interferon beta in multiple sclerosis (MS) (3 arms), sponsored by Biogen. Primary endpoint: Primary efficacy and safety assessment. Started Apr 2019; status: completed.
02
Drugs
dimethyl fumarateinterferon beta
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on MOH_2019-07-02_007245.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-07-02_007245.